pemetrexed + erlotinib
Phase 2Completed 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Non-Small-Cell Lung Cancer
Conditions
Non-Small-Cell Lung Cancer
Trial Timeline
Nov 1, 2007 → Jan 1, 2012
NCT ID
NCT00550173About pemetrexed + erlotinib
pemetrexed + erlotinib is a phase 2 stage product being developed by Eli Lilly for Non-Small-Cell Lung Cancer. The current trial status is completed. This product is registered under clinical trial identifier NCT00550173. Target conditions include Non-Small-Cell Lung Cancer.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00550173 | Phase 2 | Completed |
Competing Products
20 competing products in Non-Small-Cell Lung Cancer